Final countdown: How to transition your trials under EU-CTR

Parexel's regulatory experts shared their insight how to transition trials under EU-CTR in a live webinar on April 30. Watch on-demand to find out more about:

  1. The processes and timescales required to meet the EU-CTR trial transition deadline of 31 January 2025
  2. Actions that sponsors should take for a smooth transition process and to mitigate the risk of non-compliance as a result of missing the deadline
  3. Key learnings, insights and tips from regulatory experts with practical experience in how to approach the transition process
  4. Answers to the queries raised by our audience during the Q&A session

With the deadline for transition approaching fast, we're urging sponsors to begin the transition process for their their trials now to mitigate potential delays and the risk of trials ceasing through non-compliance with EU-CTR.

Return to Insights Center

Related Insights


New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US

Jul 16, 2024


Relyvrio Approval: Lessons Learned

Oct 31, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022


Q&A Project Optimus: What you need to know

Oct 11, 2022


Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Are you using real-world evidence?

Feb 1, 2023